AstraZeneca reported mixed phase three trial results for efzimfotase alfa, a treatment for hypophosphatasia (HPP). Positive outcomes were seen in pediatric trials, but adult and adolescent results were less clear due to a strong placebo effect. Citi maintains a buy rating and supports a $2.6 billion peak sales forecast, with potential upside to $4.4 billion, citing easier dosing and broader labeling as key advantages. Regulatory flexibility on secondary endpoints in rare diseases may also help expand the drug's market.
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
